<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670342</url>
  </required_header>
  <id_info>
    <org_study_id>NPC SSTR</org_study_id>
    <nct_id>NCT03670342</nct_id>
  </id_info>
  <brief_title>Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer</brief_title>
  <official_title>Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>A*Star</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: To estimate the proportion of locally advanced, recurrent or metastatic
      nasopharyngeal cancer patients which show high somatostatin receptor density (SUVmax &gt;10) on
      Ga-68 DOTATATE imaging.

      Galium-68 DOTATATE: PET imaging will be performed with a PET/CT scanner. Galium-68 DOTATATE
      will be injected intravenously. Scanning will be performed approximately 60 minutes after the
      injection.

      The standardized uptake value (SUV) will be used in the interpretation of the Ga-68 DOTATATE
      scans. The values gathered will be used as an estimate of the somatostatin receptor density.
      A patient will be considered to have an overall high somatostatin receptor density if the
      average SUVmax of all the representative lesions is more than 10.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2015</start_date>
  <completion_date type="Actual">April 15, 2019</completion_date>
  <primary_completion_date type="Actual">April 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of NPC patients with high somatostatin receptor density</measure>
    <time_frame>60 minutes</time_frame>
    <description>High somatostatin receptor density is when average maximum standardized uptake value (SUVmax) of all the representative lesions is more than 10 on Ga-68 DOTATATE imaging</description>
  </primary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients would have to have histologically confirmed nasopharyngeal cancer and are above 21
        years of age.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced NPC or Metastatic NPC or locally recurrent NPC

          -  &gt;21 years old

          -  Histological confirmation of NPC

        Exclusion Criteria:

          -  &lt;21 years old

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Long Nei</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>http://anpc.amegroups.com/article/view/3984/4690</url>
    <description>Somatostatin receptor imaging in nasopharyngeal cancer</description>
  </link>
  <reference>
    <citation>Nei WL, Jain A, Wang FQ, Khor LK, Yeong JP, Han ST, Sommat K, Ang MK, Soong YL, Loke KSH. Somatostatin receptor imaging in nasopharyngeal cancer. Ann Nasopharynx Cancer 2018;2:2</citation>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

